Children's oncology group's 2013 blueprint for research: Bone tumors

Richard Gorlick, Katherine Janeway, Stephen Lessnick, R. Lor Randall, Neyssa Marina

Research output: Contribution to journalReview article

92 Scopus citations

Abstract

In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.

Original languageEnglish (US)
Pages (from-to)1009-1015
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Keywords

  • Blueprint
  • Bone sarcoma
  • Ewing sarcoma
  • Osteosarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Children's oncology group's 2013 blueprint for research: Bone tumors'. Together they form a unique fingerprint.

  • Cite this

    Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., & Marina, N. (2013). Children's oncology group's 2013 blueprint for research: Bone tumors. Pediatric Blood and Cancer, 60(6), 1009-1015. https://doi.org/10.1002/pbc.24429